Navigating The Challenges Of Large, International Phase III Breast Cancer Trials

By Claudia Marques Vasconcelos, M.D., Senior Medical Director and Therapeutic Area Lead, Breast/Gynecologic Cancer, and Charlotte Moser, M.D., Ph.D., M.B.A., Chief Medical Officer

As breast cancer therapies become increasingly personalized, global Phase III trials are growing more complex to design, execute, and secure regulatory approval for. In this article, we examine how sponsors can navigate evolving biomarker requirements, regional standards of care, and demanding enrollment criteria while maintaining the statistical rigor regulators expect. From integrating advanced genomic testing to managing multinational recruitment and aligning with FDA and global regulatory expectations, successful trials now require highly coordinated operational and clinical strategies. The article highlights how adaptive study design, local regulatory expertise, and proactive site engagement can accelerate enrollment, improve data quality, and support approval pathways for next-generation therapies in an increasingly competitive breast cancer landscape.